Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands.
Identifieur interne : 000064 ( Main/Exploration ); précédent : 000063; suivant : 000065Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands.
Auteurs : N A T. Van Der Maas [Pays-Bas] ; S. Godefrooij [Pays-Bas] ; P E Vermeer-De Bondt [Pays-Bas] ; H E De Melker [Pays-Bas] ; J. Kemmeren [Pays-Bas]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2016.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Anticorps antiviraux (sang), Calendrier vaccinal (MeSH), Enquêtes et questionnaires (MeSH), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Modèles linéaires (MeSH), Mâle (MeSH), Pandémies (prévention et contrôle), Pays-Bas (épidémiologie), Saisons (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Tests d'inhibition de l'hémagglutination (MeSH), Vaccination (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- effets indésirables : Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A.
- prévention et contrôle : Grippe humaine, Pandémies.
- sang : Anticorps antiviraux.
- virologie : Grippe humaine.
- épidémiologie : Grippe humaine, Pays-Bas.
- Adjuvants immunologiques, Adulte, Adulte d'âge moyen, Calendrier vaccinal, Enquêtes et questionnaires, Femelle, Humains, Jeune adulte, Modèles linéaires, Mâle, Saisons, Sujet âgé, Sujet âgé de 80 ans ou plus, Tests d'inhibition de l'hémagglutination, Vaccination.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antibodies, Viral (blood), Female (MeSH), Hemagglutination Inhibition Tests (MeSH), Humans (MeSH), Immunization Schedule (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (virology), Linear Models (MeSH), Male (MeSH), Middle Aged (MeSH), Netherlands (epidemiology), Pandemics (prevention & control), Seasons (MeSH), Surveys and Questionnaires (MeSH), Vaccination (MeSH), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , adverse effects : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical : Adjuvants, Immunologic.
- epidemiology : Influenza, Human, Netherlands.
- immunology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human, Pandemics.
- virology : Influenza, Human.
- Adult, Aged, Aged, 80 and over, Female, Hemagglutination Inhibition Tests, Humans, Immunization Schedule, Linear Models, Male, Middle Aged, Seasons, Surveys and Questionnaires, Vaccination, Young Adult.
Abstract
In the Netherlands, people indicated for seasonal influenza vaccination are divided in 3 risk groups, i.e. those less than 60 y (y) with comorbidity and those 60 y and over with and without comorbidity. Those risk groups were also eligible for pandemic vaccination during the 2009 influenza A(H1N1) pandemic. We assessed tolerability of seasonal influenza vaccination and 2 doses of pandemic influenza A(H1N1) vaccine, adjuvanted with MF-59, administered 2 and 5 weeks after seasonal 2009-2010 vaccination among adults. Vaccinees were asked to return questionnaires on local and systemic adverse events (AEs) after each of 3 consecutive vaccinations given at the office of their General Practitioner. Sex- and risk group-specific AE-frequencies were calculated. Generalized Linear Mixed Model with seasonal vaccination as reference was used to calculate odds ratios (ORs) for AEs of the 2 pandemic doses. 5553 questionnaires (3251 vaccinees) were returned. Vaccinees reported any local AE after seasonal vaccination and both pandemic doses in 34%, 23%, and 18%, respectively. These percentages were 29%, 25%, and 16% for any systemic AE. Men reported fewer local and systemic AEs then women (p<0.0001). The risk of local (OR range 0.34-0.63) and systemic (OR range 0.39-0.99) AEs (overall, stratified by risk group and by sex) was lower after both pandemic doses compared to seasonal vaccination. This decreased risk was more pronounced after the second pandemic dose than after the first. Therefore, we conclude that MF59-adjuvanted pandemic vaccine given after seasonal vaccination was well tolerated.
DOI: 10.1080/21645515.2015.1120394
PubMed: 26809939
PubMed Central: PMC4962940
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands.</title><author><name sortKey="Van Der Maas, N A T" sort="Van Der Maas, N A T" uniqKey="Van Der Maas N" first="N A T" last="Van Der Maas">N A T. Van Der Maas</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation></author><author><name sortKey="Godefrooij, S" sort="Godefrooij, S" uniqKey="Godefrooij S" first="S" last="Godefrooij">S. Godefrooij</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>b Department of Health Science, VU University Amsterdam , Amsterdam , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>b Department of Health Science, VU University Amsterdam , Amsterdam </wicri:regionArea><wicri:noRegion>Amsterdam </wicri:noRegion></affiliation></author><author><name sortKey="Vermeer De Bondt, P E" sort="Vermeer De Bondt, P E" uniqKey="Vermeer De Bondt P" first="P E" last="Vermeer-De Bondt">P E Vermeer-De Bondt</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation></author><author><name sortKey="De Melker, H E" sort="De Melker, H E" uniqKey="De Melker H" first="H E" last="De Melker">H E De Melker</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation></author><author><name sortKey="Kemmeren, J" sort="Kemmeren, J" uniqKey="Kemmeren J" first="J" last="Kemmeren">J. Kemmeren</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26809939</idno><idno type="pmid">26809939</idno><idno type="doi">10.1080/21645515.2015.1120394</idno><idno type="pmc">PMC4962940</idno><idno type="wicri:Area/Main/Corpus">000074</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000074</idno><idno type="wicri:Area/Main/Curation">000074</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000074</idno><idno type="wicri:Area/Main/Exploration">000074</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands.</title><author><name sortKey="Van Der Maas, N A T" sort="Van Der Maas, N A T" uniqKey="Van Der Maas N" first="N A T" last="Van Der Maas">N A T. Van Der Maas</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation></author><author><name sortKey="Godefrooij, S" sort="Godefrooij, S" uniqKey="Godefrooij S" first="S" last="Godefrooij">S. Godefrooij</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>b Department of Health Science, VU University Amsterdam , Amsterdam , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>b Department of Health Science, VU University Amsterdam , Amsterdam </wicri:regionArea><wicri:noRegion>Amsterdam </wicri:noRegion></affiliation></author><author><name sortKey="Vermeer De Bondt, P E" sort="Vermeer De Bondt, P E" uniqKey="Vermeer De Bondt P" first="P E" last="Vermeer-De Bondt">P E Vermeer-De Bondt</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation></author><author><name sortKey="De Melker, H E" sort="De Melker, H E" uniqKey="De Melker H" first="H E" last="De Melker">H E De Melker</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation></author><author><name sortKey="Kemmeren, J" sort="Kemmeren, J" uniqKey="Kemmeren J" first="J" last="Kemmeren">J. Kemmeren</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven </wicri:regionArea><wicri:noRegion>Bilthoven </wicri:noRegion></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antibodies, Viral (blood)</term><term>Female (MeSH)</term><term>Hemagglutination Inhibition Tests (MeSH)</term><term>Humans (MeSH)</term><term>Immunization Schedule (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Linear Models (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Netherlands (epidemiology)</term><term>Pandemics (prevention & control)</term><term>Seasons (MeSH)</term><term>Surveys and Questionnaires (MeSH)</term><term>Vaccination (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps antiviraux (sang)</term><term>Calendrier vaccinal (MeSH)</term><term>Enquêtes et questionnaires (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (virologie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Modèles linéaires (MeSH)</term><term>Mâle (MeSH)</term><term>Pandémies (prévention et contrôle)</term><term>Pays-Bas (épidémiologie)</term><term>Saisons (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Tests d'inhibition de l'hémagglutination (MeSH)</term><term>Vaccination (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Pandémies</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>Pays-Bas</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Immunization Schedule</term><term>Linear Models</term><term>Male</term><term>Middle Aged</term><term>Seasons</term><term>Surveys and Questionnaires</term><term>Vaccination</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier vaccinal</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Modèles linéaires</term><term>Mâle</term><term>Saisons</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the Netherlands, people indicated for seasonal influenza vaccination are divided in 3 risk groups, i.e. those less than 60 y (y) with comorbidity and those 60 y and over with and without comorbidity. Those risk groups were also eligible for pandemic vaccination during the 2009 influenza A(H1N1) pandemic. We assessed tolerability of seasonal influenza vaccination and 2 doses of pandemic influenza A(H1N1) vaccine, adjuvanted with MF-59, administered 2 and 5 weeks after seasonal 2009-2010 vaccination among adults. Vaccinees were asked to return questionnaires on local and systemic adverse events (AEs) after each of 3 consecutive vaccinations given at the office of their General Practitioner. Sex- and risk group-specific AE-frequencies were calculated. Generalized Linear Mixed Model with seasonal vaccination as reference was used to calculate odds ratios (ORs) for AEs of the 2 pandemic doses. 5553 questionnaires (3251 vaccinees) were returned. Vaccinees reported any local AE after seasonal vaccination and both pandemic doses in 34%, 23%, and 18%, respectively. These percentages were 29%, 25%, and 16% for any systemic AE. Men reported fewer local and systemic AEs then women (p<0.0001). The risk of local (OR range 0.34-0.63) and systemic (OR range 0.39-0.99) AEs (overall, stratified by risk group and by sex) was lower after both pandemic doses compared to seasonal vaccination. This decreased risk was more pronounced after the second pandemic dose than after the first. Therefore, we conclude that MF59-adjuvanted pandemic vaccine given after seasonal vaccination was well tolerated.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26809939</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>04</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands.</ArticleTitle><Pagination><MedlinePgn>1027-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1120394</ELocationID><Abstract><AbstractText>In the Netherlands, people indicated for seasonal influenza vaccination are divided in 3 risk groups, i.e. those less than 60 y (y) with comorbidity and those 60 y and over with and without comorbidity. Those risk groups were also eligible for pandemic vaccination during the 2009 influenza A(H1N1) pandemic. We assessed tolerability of seasonal influenza vaccination and 2 doses of pandemic influenza A(H1N1) vaccine, adjuvanted with MF-59, administered 2 and 5 weeks after seasonal 2009-2010 vaccination among adults. Vaccinees were asked to return questionnaires on local and systemic adverse events (AEs) after each of 3 consecutive vaccinations given at the office of their General Practitioner. Sex- and risk group-specific AE-frequencies were calculated. Generalized Linear Mixed Model with seasonal vaccination as reference was used to calculate odds ratios (ORs) for AEs of the 2 pandemic doses. 5553 questionnaires (3251 vaccinees) were returned. Vaccinees reported any local AE after seasonal vaccination and both pandemic doses in 34%, 23%, and 18%, respectively. These percentages were 29%, 25%, and 16% for any systemic AE. Men reported fewer local and systemic AEs then women (p<0.0001). The risk of local (OR range 0.34-0.63) and systemic (OR range 0.39-0.99) AEs (overall, stratified by risk group and by sex) was lower after both pandemic doses compared to seasonal vaccination. This decreased risk was more pronounced after the second pandemic dose than after the first. Therefore, we conclude that MF59-adjuvanted pandemic vaccine given after seasonal vaccination was well tolerated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Maas</LastName><ForeName>N A T</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godefrooij</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Department of Health Science, VU University Amsterdam , Amsterdam , the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeer-de Bondt</LastName><ForeName>P E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Melker</LastName><ForeName>H E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemmeren</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558220">focetria</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">adverse event following immunization</Keyword><Keyword MajorTopicYN="Y">influenza</Keyword><Keyword MajorTopicYN="Y">pandemic</Keyword><Keyword MajorTopicYN="Y">seasonal</Keyword><Keyword MajorTopicYN="Y">tolerability</Keyword><Keyword MajorTopicYN="Y">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26809939</ArticleId><ArticleId IdType="doi">10.1080/21645515.2015.1120394</ArticleId><ArticleId IdType="pmc">PMC4962940</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Clin Pract. 2010 Mar;64(4):432-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20039974</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1999 Jul 30;17 Suppl 1:S3-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10471173</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 2009 Aug;21(4):418-24</Citation><ArticleIdList><ArticleId IdType="pubmed">19570667</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Nov 16;27(49):6959-65</Citation><ArticleIdList><ArticleId IdType="pubmed">19751689</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Risk Saf Med. 2011;23(2):81-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21673415</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Jul 13;30(33):5030-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22472791</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Nov 20;32(49):6622-30</Citation><ArticleIdList><ArticleId IdType="pubmed">25446824</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Feb 24;29(10):1941-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21236235</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Oct 23;27(45):6300-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19840664</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20689501</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Van Der Maas, N A T" sort="Van Der Maas, N A T" uniqKey="Van Der Maas N" first="N A T" last="Van Der Maas">N A T. Van Der Maas</name></noRegion><name sortKey="De Melker, H E" sort="De Melker, H E" uniqKey="De Melker H" first="H E" last="De Melker">H E De Melker</name><name sortKey="Godefrooij, S" sort="Godefrooij, S" uniqKey="Godefrooij S" first="S" last="Godefrooij">S. Godefrooij</name><name sortKey="Godefrooij, S" sort="Godefrooij, S" uniqKey="Godefrooij S" first="S" last="Godefrooij">S. Godefrooij</name><name sortKey="Kemmeren, J" sort="Kemmeren, J" uniqKey="Kemmeren J" first="J" last="Kemmeren">J. Kemmeren</name><name sortKey="Vermeer De Bondt, P E" sort="Vermeer De Bondt, P E" uniqKey="Vermeer De Bondt P" first="P E" last="Vermeer-De Bondt">P E Vermeer-De Bondt</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippePaysBasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000064 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000064 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippePaysBasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26809939
|texte= Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26809939" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippePaysBasV1
| This area was generated with Dilib version V0.6.35. |  |